NEWTOWN, Pa., Feb. 24, 2020 -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US.

This prestigious award, presented by the Brain Mapping Foundation (BMF) and Society for Brain Mapping and Therapeutics (SBMT), is given to trailblazing technology companies and their CEOs/Presidents who have facilitated the development of pioneering technologies through interdisciplinary approaches that have impacted diagnostics, treatment, and healthcare delivery in unprecedented ways.

A live webcast of the call will also be provided on the Events section of the Company's investor relations website and can be accessed directly via the following link: https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/36950/indexl.html. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13698861. The webcast will be archived on the Events section of the Company’s investor relations website.

Helius’ Portable Neuromodulation Stimulator (PoNS™) device is now authorized to be marketed for the short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy, in addition to the short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. “We are very pleased to receive regulatory clearance to market our PoNS Treatment to the approximately 93,500 patients in Canada who suffer from MS,” said Philippe Deschamps, Chief Executive Officer of Helius.

Beginning in the third quarter of 2019, we also made important changes to our commercial strategy in Canada, acquiring the Heuro Canada operating entity and establishing an internal team to lead our commercial efforts going forward. During the fourth quarter of 2019, and in recent months, we enhanced our targeting criteria for the clinics with which we engage and authorize to provide PoNS Treatment, prioritizing clinics that have established commercial operations, strong referral networks with local neurological hospitals and reimbursement and an exclusive focus on neurorehabilitation.

The Cline Medical Centre in Nanaimo is the Eighth Authorized PoNS Treatment™ Clinic in Canada. Cline Medical Centre is a leading integrative and functional medicine healthcare facility located at 2090 Skaha Drive, Nanaimo, BC.

"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

“We are extremely pleased to receive this designation for our PoNS device,” said Philippe Deschamps, the Company’s CEO. “We look forward to working with FDA to process our application, with the ultimate goal of bringing our innovative technology to the aid of patients suffering with gait deficit due to MS-related symptoms, by providing them with a non-drug, non-implantable treatment that has the potential to significantly improve their ability to walk.” The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Helius has now expanded access for patients seeking PoNS Treatment to fourteen clinics in Canada, with eight in Ontario, the most populous province. “Our progress in authorizing seven new clinics during the first two months of 2020 reflects the success of our new commercial strategy to enhance clinic engagement and increase the adoption of our PoNS Treatment,” said Philippe Deschamps, Chief Executive Officer of Helius.

A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/35777/indexl.html. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13698861. The webcast will be archived on the Events section of the Company’s investor relations website.

NEWTOWN, Pa., May 07, 2020 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today.

KITE is the research arm of the Toronto Rehabilitation Institute and one of the principle research enterprises at the University Health Network (UHN), Canada’s largest medical research hospital. KITE is a world leader in the field of complex rehabilitation research, with scientists and staff dedicated to improving the lives of people living with the effects of disability, illness and aging.

If you own shares in Helius Medical Technologies, Inc. (NASDAQ:HSDT) then it's worth thinking about how it contributes...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (the “Company”), a neurotech company focused on neurological wellness, announced today that the results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury (“mmTBI”) have been published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation. The newly published results from the double-blind randomized clinical trial which paired translingual neurostimulation using the Portable Neuromodulation Stimulator (PoNS™) device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment.

Helius also agreed to issue to the investors unregistered warrants to purchase up to 6,257,144 shares of its common stock. The warrants have an exercise price of $0.46 per share of common stock, will be exercisable on September 20, 2020, and will expire five years following the initial exercisability date. The closing of the sale of the securities is expected to occur on or about March 20, 2020, subject to the satisfaction of customary closing conditions.

NEWTOWN, Pa., March 12, 2020 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.

The TBI-001 trial found that PoNS Treatment™ provided significant improvement in balance in patients with a chronic balance deficit following a mild-to-moderate traumatic brain injury (“mmTBI”). This newly-published, 122 subject, multicenter, double-blind randomized clinical trial, found that the PoNS Treatment, which pairs translingual neurostimulation using the Portable Neuromodulation Stimulator (PoNS™) device with therapeutic activities, significantly improves balance and gait.

NEWTOWN, Pa., Jan. 16, 2020 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.

Upon his appointment, Mr. Mathiesen will serve as Chair of the Company’s Audit Committee. “Jeff joins our Board of Directors with more than 25 years of experience as Chief Financial Officer of numerous growth-oriented, technology-based companies, including significant experience in the healthcare sector,” said Philippe Deschamps, Chief Executive Officer of Helius Medical Technologies and Chairman of the Board of Directors.